Payment overview · 2025
General Payments
$474.86
19 reported records · 10 companies
Healthcare provider profile · identity verified
Cory Ruddy-Ramirez, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BRONX, NY · NPI 1538422944
Verified facts
What the public records show
CMS Open Payments records show Cory Ruddy-Ramirez, D.O. received $474.86 in general payments during 2025 across 19 reported records.
GlaxoSmithKline, LLC. accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ubrelvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $118.58 | 25.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $93.60 | 19.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.23 | 12.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.59 | 12.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $53.25 | 11.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.55 | 4.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.51 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.02 | 3.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.96 | 3.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.57 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $474.86 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $118.58 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $93.60 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.15 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.23 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.59 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $53.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.98 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 225 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
225 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 565 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 125 |
| Lisinopril | Lisinopril | 295 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 258 | 61 |
| Omeprazole | Omeprazole | 239 | 70 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 225 | 32 |
| Gabapentin | Gabapentin | 206 | 40 |
| Metformin Hcl | Metformin Hcl | 196 | 59 |
| Ozempic | Semaglutide | 171 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 35 |
| Losartan Potassium | Losartan Potassium | 114 | 28 |
| Montelukast Sodium | Montelukast Sodium | 113 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 36 |
| Meclizine Hcl | Meclizine Hcl | 109 | 21 |
| Famotidine | Famotidine | 105 | 30 |
| Naproxen | Naproxen | 105 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 16 |
| Lidocaine | Lidocaine | 90 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 89 | 23 |
| Trulicity | Dulaglutide | 89 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 86 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 84 | 24 |
| Ammonium Lactate | Ammonium Lactate | 74 | 19 |
| Ibuprofen | Ibuprofen | 74 | 23 |
| Ezetimibe | Ezetimibe | 67 | 19 |
| Nifedipine Er | Nifedipine | 67 | 14 |
| Celecoxib | Celecoxib | 66 | 13 |
| Furosemide | Furosemide | 65 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | suppressed |
| Pregabalin | Pregabalin | 60 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | 12 |
| Meloxicam | Meloxicam | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 18 |
| Prednisone | Prednisone | 53 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 16 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Carvedilol | Carvedilol | 47 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | 15 |
| Farxiga | Dapagliflozin Propanediol | 45 | 14 |
| Spironolactone | Spironolactone | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 17 |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Ubrelvy | Ubrogepant | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 31 | 14 |
| Topiramate | Topiramate | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Clotrimazole | Clotrimazole | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 11 |
| Azithromycin | Azithromycin | 26 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 18 |
| Latanoprost | Latanoprost | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Dexilant | Dexlansoprazole | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $474.86 · 19 records | GlaxoSmithKline, LLC. | ACCRUFER, Cologuard Collection Kit, ELIQUIS, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, Symbravo, TRELEGY ELLIPTA, UBRELVY, Veozah, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error